VITACCESS DONATES £10,000 TO MELANOMA UK

Award-winning digital health company Vitaccess is delighted to announce that, as part of their syndicated project with patient support charity Melanoma UK, they are donating £10,000 towards an Adamo Horus HS800 mole mapper for the Royal Liverpool and Broadgreen University Hospitals NHS Trust.

Cheque donation #1.jpg

Back in October 2017, Vitaccess, Melanoma UK and The Royal Marsden NHS Foundation Trust joined forces to create the innovative patient-centric Melanoma UK app. The project financed by Vitaccess is based on profit share with the charity Melanoma UK, and the Vitaccess team couldn’t be more proud to see its first app-based research study reach that key milestone.

Subscriptions from pharmaceutical company researchers to access the anonymised and aggregated dataset collected since the start of the project, enable Vitaccess to make this valuable donation.

The study app collects data from people living with melanoma, such as quality of life, treatment patterns, demographic and epidemiological data across all stages of disease, treatment, and beyond. The advantages of electronic data collection as opposed to paper data collection in a healthcare or clinical trial setting are well documented and include reduced administrative burden for participants and administrators; the avoidance of errors in data collection and entry; and fewer items of missing data.

Data are collected in the real-world setting using “bring your own device” (BYOD) technology – participants use their own smartphone to complete questionnaires and surveys at their own convenience. A brand new rewards scheme launched last month gives participants the chance to raise money for Melanoma UK by raising £1 per survey.   

The app features are updated regularly to enhance user experience. Vitaccess send out regular patient feedback surveys and host calls and workshops to take into account what patients think could improve the Melanoma UK app.

Mark Diane + 1 person hospital.jpg

This study helps the research community to understand how people are during what has become routine treatment, and afterwards. The pilot stage is collecting data in the UK but the plan is to extend data collection globally in the US, Europe and Australia.

Dr Mark Larkin, Vitaccess CEO commented: “We are thrilled to have reached the point where we can give back to the community with this donation. A lot of work has gone into the creation of the Melanoma UK app and it is very rewarding not only to hear how useful it is to patients, but to be able to support projects that are meaningful for them, such as mole mapper units going into NHS hospitals. The collection of real-world evidence provides a map of how melanoma impacts the daily life of patients in near real-time. Access to this information helps not only the industry in their research but also academic researchers who can access it for free by application to the scientific board.

Diane Cannon, Corporate Partnership Director at Melanoma UK enthusiastically added: “With this app, Mark’s team has provided Melanoma UK with the first digital registry of its kind. Bringing patients a tool that allows them to manage their condition whilst helping research at the same time was a ground-breaking idea. To now see them supporting Melanoma UK in our bid to equip as many NHS hospitals as possible with Adamo’s body mole mappers is such a tangible and game-changing result of our partnership. Mole analysing and body mapping technology helps detect melanoma and skin cancer very early on and, as we’ve seen thanks to the registry, the outcomes look more positive when you get diagnosed early.

ENDS

For further information, please contact:

Vitaccess - Coralie Rassinoux

by email at coralie.rassinoux@vitaccess.com or by phone at +44 (0) 1865 818 983/+44 (0) 751 323 0598

Melanoma UK – Diane Cannon

by email at diane.cannon@melanomauk.org.uk or by phone at +44 (0) 750 147 6894

Notes to Editors

Melanoma UK is a unique charity: it is run by a team of people who have all been affected by melanoma. The fact that we have all been affected by the disease enables us to put ourselves in the shoes of a patient, a carer or a family member. Melanoma is a brutal disease and one which does not have a cure. However, great scientific strides are being made and patients now have more treatment options than they have ever had before. Melanoma UK operates a free 24-hour help line 0808 117 2455. Contact can be made via the Melanoma UK website.

Vitaccess is an award-winning digital-health and strategic consultancy, founded in 2014. Though based in Oxford, UK, our reach is truly global. We offer a world-class real-world evidence (RWE) data portfolio and data science research via MyRealWorld™, our state-of-the-art digital platform, and experience-based Market Access and Health Economics and Outcomes Research (HEOR) solutions.

Our heritage in HEOR and Market Access makes us a trusted partner to the pharmaceutical industry. We understand the importance of scientific rigour in RWE studies, as well as the complexities of information governance - including GDPR and HIPAA. Industry standards have been applied to the creation of our pioneering and flexible digital platform, MyRealWorld™, through which we capture RWE in real-time, to be transmitted in aggregated, anonymised form to customisable and interactive research dashboards.

MyRealWorldTM, the patient’s voice, digitally

Our powerful RWE platform quantifies patients’ experiences of illnesses and treatments in everyday work-, social- and home-life, which can be very different from the impact measured in clinical trials.

We can produce smartphone (iOS/Android) apps tailored to any indication, country or language, for use on any device, and we can customize data collection to individual study requirements.

HEOR and Market Access, optimised

We develop effective and pragmatic recommendations that optimize patient access and maximise success at health technology assessment (HTA). Our approach is grounded in detailed and up-to-the-minute understanding of the global pricing and reimbursement landscape, supported by analytic rigour and insight.

Coralie Rassinoux